Anti-cea antibodies
AssigneePhilogen S.P.A.
InventorsLouis PLÜSS, Roberto DE LUCA, Abdullah ELSAYED, Frederik PEISSERT, Dario NERI
Life of this patent
Estimating the term…
Abstract
Anti-CEA Antibodies The application relates to the diagnosis and treatment of diseases, including cancer. The invention provides, and involves the use of, antibody molecules that bind carcinoembryonic antigen (CEA) from humans. The antibody molecules may be conjugated to a pro-inflammatory agent, a biocidal molecule, a cytotoxic molecule, or a radioisotope. The antibody molecules may form part of a bispecific molecule which binds a T cell antigen, such as CD3.
Claims21
A antibody molecule that binds the N-terminal domain of carcinoembryonic antigen (CEA), wherein the antibody molecule comprises a VH domain comprising a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, and a VL domain comprising a set of complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein:
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs 2, 3 and 4, respectively, and
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs 5, 6 and 7, respectively.
-21. (canceled)
Dependencies are inferred from the claim text.